Anemia, PO DM meds Flashcards
first line if A1C is <7.5%
metformin
site of action: Alpha Glucosidase Inhibitors
intestines
class: Acarbose, miglitol
Alpha Glucosidase Inhibitors
site of action: Meglitinides
pancreas
class: Repaglinide, nateglinide
Meglitinides
main SE of Repaglinide, nateglinide
hypoglycemia (severe if also on gemfibrozil)
site of action: Sulfonylureas
pancreas
class: Glyburide, glipizide, glimepiride
Sulfonylureas
MOA: blocks ATP sensitive K channels – insulin release from functional beta cells, decreased efficacy w/ time
o Increases insulin secretion
Sulfonylureas
AEs: **Hypoglycemia
o Weight gain
o Nausea, dyspepsia, diarrhea
Sulfonylureas
cautions: Sulfonylureas
elderly, renal and hepatic dysfunction
CI: Sulfonylureas
pregnancy, sulfa allergy, type 1 DM
site of action: Biguanides
liver, muscle
class: metformin
Biguanides
initial dosing for metformin
IR 500mg Qd or bid / XR 500mg QD
MOA: reduces liver gluconeogenesis and glycogenolysis
o Decreases liver glucose formation/release
o Increase glucose uptake by skeletal muscle and adipose tissue à increases insulin sensitivity
metformin
metformin - hypoglycemia risk as monotherapy?
no
AEs: ovulation, N/V/**D, flatulence, macrocytic anemia / peripheral neuropathy – must monitor renal function and Vit B12
metformin
BBW: metformin
LACTIC ACIDOSIS
§ in pts w/ CHF, hepatic or renal dysfunction, elderly, alcohol abuse
stie of action: Thiazolidinediones (Glitazones)
liver, muscle, adipose tissue
class: Pioglitazone, rosiglitazone
Thiazolidinediones (Glitazones)
MOA: PPARg agonist à increase GLUT-4 transporters, increase insulin sensitivity of tissues. decreases gluconeogenesis
Thiazolidinediones (Glitazones)